{"classes":[{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation (CV) was not calculated as data were available for only two participants.","groupId":"OG000","spread":"NA","value":"49.0"},{"groupId":"OG001","spread":"61.1","value":"50.0"},{"groupId":"OG002","spread":"37.6","value":"149"},{"groupId":"OG003","spread":"46.8","value":"205"},{"groupId":"OG004","spread":"37.5","value":"262"},{"groupId":"OG005","spread":"37.1","value":"387"},{"groupId":"OG006","spread":"44.4","value":"407"},{"groupId":"OG007","spread":"36.6","value":"416"},{"groupId":"OG008","spread":"18.5","value":"670"},{"groupId":"OG009","spread":"41.4","value":"583"},{"groupId":"OG010","spread":"33.2","value":"668"},{"groupId":"OG011","spread":"32.4","value":"800"},{"groupId":"OG012","spread":"49.3","value":"1068"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"8"},{"groupId":"OG012","value":"5"}],"units":"Participants"}],"description":"Cmax was defined as the maximum observed concentration, taken directly from the plasma concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received selinexor dose of 3 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 5, 8, 10, 15, 17, 19, 22 and 24 in schedule 1.","id":"OG000","title":"Selinexor (3 mg/m^2)"},{"description":"Participants received selinexor dose of 6 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 5, 8, 10, 15, 17, 19, 22 and 24 in schedule 1.","id":"OG001","title":"Selinexor (6 mg/m^2)"},{"description":"Participants received selinexor dose of 12 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 5, 8, 10, 15, 17, 19, 22 and 24 in schedule 1.","id":"OG002","title":"Selinexor (12 mg/m^2)"},{"description":"Participants received selinexor dose of 16.8 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 5, 8, 15, 17, 19, and 22 in schedule 2.","id":"OG003","title":"Selinexor (16.8 mg/m^2)"},{"description":"Participants received selinexor dose of 23 mg/m\\^2 orally at Cycle 1, on Day 1 and 2 of each week for a 28-day cycle in schedule 4.","id":"OG004","title":"Selinexor (23 mg/m^2)"},{"description":"Participants received selinexor dose of 30 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 4, 8, 10, 15 and 17 in schedule 3, 5 and 9.","id":"OG005","title":"Selinexor (30 mg/m^2)"},{"description":"Participants received selinexor dose of 35 mg/m\\^2 orally at Cycle 1, on Day 1 and 3 in schedule 6.","id":"OG006","title":"Selinexor (35 mg/m^2)"},{"description":"Participants received selinexor dose of 40 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 8, 10, 15, 17 followed by an 11-day treatment-free interval (Days 18 through 28) in schedule 8 and 11.","id":"OG007","title":"Selinexor (40 mg/m^2)"},{"description":"Participants received selinexor dose of 46 mg/m\\^2 orally at Cycle 1, on Day 1 once-weekly in schedule 7.","id":"OG008","title":"Selinexor (46 mg/m^2)"},{"description":"Participants received selinexor dose of 55 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 8, and 10, followed by an 18-day treatment-free interval (Days 11 through 28) in schedule 10.","id":"OG009","title":"Selinexor (55 mg/m^2)"},{"description":"Participants received selinexor dose of 60 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 8, 10, 15, and 17, followed by an 11-day treatment-free interval (Days 18 through 28) in schedule 11.","id":"OG010","title":"Selinexor (60 mg/m^2)"},{"description":"Participants received selinexor dose of 70 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 8, 10, 15, and 17, followed by an 11-day treatment-free interval (Days 18 through 28) in schedule 11.","id":"OG011","title":"Selinexor (70 mg/m^2)"},{"description":"Participants received selinexor dose of 80 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 8, 10, 15, and 17, followed by an 11-day treatment-free interval (Days 18 through 28) in schedule 11.","id":"OG012","title":"Selinexor (80 mg/m^2)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) analysis was defined as all participants who received active drug, selinexor, without the co-administration of another chemotherapeutic (i.e., rituximab), and for whom the PK profile for cycle 1 day1 (C1D1) could be adequately characterized. Here 'Overall Number of Participants Analyzed' signifies number of participants analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"0 (pre-dose), 0.5, 1, 2, 4, 8, 24 and 48 hours post-dose on Day 1, 8 of Cycle 1 and Days 15, 16 or 17 of Cycle 2","title":"Maximum Observed Plasma Concentration (Cmax) of Selinexor","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}